First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
(2012) In Journal of Cancer Research and Clinical Oncology 138(1). p.65-72- Abstract
- Purpose Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC. Methods In this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m(2)) and leucovorin (400 mg/m(2)) followed by a 5-fluorouracil 400 mg/m(2) bolus and a 2,400-3,000 mg/m(2) continuous infusion] were administered every 14 days until progression. Data were analysed descriptively overall and by tumour KRAS status. Results KRAS data were available for 145/154 (94%) patients: 59% KRAS WT and 41% mutant (MT); mean follow-up was 39.5 versus 35.8 weeks, respectively. Objective responses... (More)
- Purpose Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC. Methods In this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m(2)) and leucovorin (400 mg/m(2)) followed by a 5-fluorouracil 400 mg/m(2) bolus and a 2,400-3,000 mg/m(2) continuous infusion] were administered every 14 days until progression. Data were analysed descriptively overall and by tumour KRAS status. Results KRAS data were available for 145/154 (94%) patients: 59% KRAS WT and 41% mutant (MT); mean follow-up was 39.5 versus 35.8 weeks, respectively. Objective responses occurred in 49% of patients: 56% versus 38% in the KRAS WT versus MT groups [(18% difference (95% CI 1-35%); odds ratio 2.1 (95% CI 1.0-4.4)]; median duration of response was 13.0 versus 7.4 months. More patients in the WT group underwent R0 resection (8% vs. 5%); median progression-free survival also favoured this group (8.9 vs. 7.2 months). The most common adverse events (any grade) were integument toxicities (98%), diarrhoea (79%) and stomatitis/oral mucositis (51%). Conclusions As expected, consistently favourable efficacy was observed in patients with KRAS WT versus MT tumours receiving first-line panitumumab plus FOLFIRI treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2409693
- author
- Koehne, Claus-Henning ; Hofheinz, Ralf ; Mineur, Laurent ; Letocha, Henry ; Greil, Richard ; Thaler, Josef ; Fernebro, Eva LU ; Gamelin, Erick ; DeCosta, Lucy and Karthaus, Meinolf
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chemotherapy, Fully human monoclonal antibody, Metastatic colorectal, cancer, Panitumumab
- in
- Journal of Cancer Research and Clinical Oncology
- volume
- 138
- issue
- 1
- pages
- 65 - 72
- publisher
- Springer
- external identifiers
-
- wos:000300344500007
- scopus:84857050570
- pmid:21960318
- ISSN
- 1432-1335
- DOI
- 10.1007/s00432-011-1061-6
- language
- English
- LU publication?
- yes
- id
- 254cce28-3a88-42c1-95da-d82ee9a9d5a7 (old id 2409693)
- date added to LUP
- 2016-04-01 10:15:55
- date last changed
- 2022-01-25 21:33:39
@article{254cce28-3a88-42c1-95da-d82ee9a9d5a7,
abstract = {{Purpose Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC. Methods In this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m(2)) and leucovorin (400 mg/m(2)) followed by a 5-fluorouracil 400 mg/m(2) bolus and a 2,400-3,000 mg/m(2) continuous infusion] were administered every 14 days until progression. Data were analysed descriptively overall and by tumour KRAS status. Results KRAS data were available for 145/154 (94%) patients: 59% KRAS WT and 41% mutant (MT); mean follow-up was 39.5 versus 35.8 weeks, respectively. Objective responses occurred in 49% of patients: 56% versus 38% in the KRAS WT versus MT groups [(18% difference (95% CI 1-35%); odds ratio 2.1 (95% CI 1.0-4.4)]; median duration of response was 13.0 versus 7.4 months. More patients in the WT group underwent R0 resection (8% vs. 5%); median progression-free survival also favoured this group (8.9 vs. 7.2 months). The most common adverse events (any grade) were integument toxicities (98%), diarrhoea (79%) and stomatitis/oral mucositis (51%). Conclusions As expected, consistently favourable efficacy was observed in patients with KRAS WT versus MT tumours receiving first-line panitumumab plus FOLFIRI treatment.}},
author = {{Koehne, Claus-Henning and Hofheinz, Ralf and Mineur, Laurent and Letocha, Henry and Greil, Richard and Thaler, Josef and Fernebro, Eva and Gamelin, Erick and DeCosta, Lucy and Karthaus, Meinolf}},
issn = {{1432-1335}},
keywords = {{Chemotherapy; Fully human monoclonal antibody; Metastatic colorectal; cancer; Panitumumab}},
language = {{eng}},
number = {{1}},
pages = {{65--72}},
publisher = {{Springer}},
series = {{Journal of Cancer Research and Clinical Oncology}},
title = {{First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer}},
url = {{http://dx.doi.org/10.1007/s00432-011-1061-6}},
doi = {{10.1007/s00432-011-1061-6}},
volume = {{138}},
year = {{2012}},
}